The Effects of Nextida-GC and Whey Protein on Postprandial Glycemic and Insulinemic Responses When Given 30min Before, 10min Before or With a Standardized Breakfast Test-meal in Healthy Adults With and Without Prediabetes

NCT07174323 | Completed

• 1 other identifier: INQ-2504
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

The goals of this clinical trial are to learn if Nextida-GC (a peptide derived from collagen) will reduce postprandial glucose responses when taken 30 minutes before, 10 minutes before or with the first bite of a breakfast test-meal consisting or bread, margarine and jam with a drink coffee, tea or water (each subject will choose a drink and have the same drink each time). The main questions it aims to answer are: Does Nextida-GC reduce glucose responses more than whey protein? What are the effects of Nextida-GC and whey protein on plasma glucose and serum insulin responses when given 30 minutes before eating, 10 minutes before eating, or with the breakfast test meal? Overall, is it better to take Nextida-GC 30 minutes before eating, 10 minutes before eating, or with the breakfast test meal? Participants will: Come to the research center (INQUIS Clinical Research, Toronto, Ontario, Canada) on 8 separate occasions (with bewteen 3 and 14 days between visits) after an overnight fast of at least 10 hours. Each participant will undergo all 8 treatments (one treatment per visit): Block 1

• 10 grams Nextida-GC in water 30 minutes before eating the test-meal
• 10 grams Nextida-GC in water 10 minutes before eating the test-meal
• water 30min before eating and 10g Nextida-GC in water with the test-meal
• water 30min before eating, and water with the test-meal Block 2
• 10 grams whey protein in water 30 minutes before eating the test-meal
• 10 grams whey protein in water 10 minutes before eating the test-meal
• water 30min before eating and 10g whey protein in water with the test-meal
• water 30min before eating, and water with the test-meal The order of the blocks will be randomized and the order of the treatments within the blocks will be randomized. On each occasions finger-stick blood samples for measuring glucose and insulin will be obtained 30, 10 and 0 minutes before starting to eat the test-meal and 15, 30, 45, 60, 90, 120 and 180 minutes after the first bite of the test-meal. The main outcome of the study is the area under the curve of plasma glucose from 0 to 180 minutes.

Conditions

Prediabetes; Normal Plasma Glucose; Normoglycemia

Keywords

Glucose; Insulin; prediabetes; whey protein; collagen protein; preload

Outcome Measures

Primary Outcomes (1)

• Glucose iAUC 0-180

  Incremental area under the glucose curve (iAUC), ignoring area below the concentration at 0 min (just before starting to eat), calculated from plasma glucose measured at 15, 30, 45, 60, 90, 120 and 180 min after starting to eat.

  0 min to 180 minutes

Secondary Outcomes (7)

• Insulin AUC 0-180

  0-180 minutes

• Glucose Peak Rise

  0-180 minutes

• Insulin Peak Rise

  0-180 minutes

• MAGE

  0-180 minutes

• Glucose Time In Range (TIR)

  0-180 min

Study Arms (4)

-30 min

ACTIVE COMPARATOR

10 g protein 30 min before eating

Dietary Supplement: Peptide derived from collagen protein; Dietary Supplement: Whey protein isolate

-10 minutes

ACTIVE COMPARATOR

10 g protein 10 min before eating

Dietary Supplement: Peptide derived from collagen protein; Dietary Supplement: Whey protein isolate

Control

SHAM COMPARATOR

•200 ml water with no protein

Dietary Supplement: Peptide derived from collagen protein; Dietary Supplement: Whey protein isolate

0 minutes

ACTIVE COMPARATOR

10 g protein with test meal

Dietary Supplement: Peptide derived from collagen protein; Dietary Supplement: Whey protein isolate

Interventions

Whey protein isolate DIETARY_SUPPLEMENT

Whey protein isolate

-10 minutes; -30 min; 0 minutes; Control

Peptide derived from collagen protein DIETARY_SUPPLEMENT

Peptide derived from collagen protein

-10 minutes; -30 min; 0 minutes; Control

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Non-pregnant, non-lactating.
• BMI 18.5 to 35.0 kg/m² inclusive.
• n=20 with prediabetes: fasting glucose 5.6-6.9 mmol/L and/or HbA1c 5.7-6.4%.
• n=12 without prediabetes: fasting glucose \<5.6 mmol/L and HbA1c \<5.7%.
• Systolic blood pressure \<160mmHg and diastolic blood pressure \<100mmHg.
• Willing to abstain from unusual strenuous exercise and consuming alcoholic drinks for 24 hours before study days.
• Willing to refrain from smoking tobacco or using marijuana in any form (including but not limited to smoking, vaping, edibles, tinctures, or other ingestible or inhalable preparations) for 12h before and during study visits.
• Willing to consume study products that contain animal derived ingredients
• Understand the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.
• Eligible to receive income in Canada and covered by a health insurance plan such as OHIP.

You may not qualify if:

• Major trauma or surgical event within 3 months of screening.
• Use of supplements containing collagen and/or high dose of chromium (\>500mcg).
• The presence of any laboratory result, health condition, illness or drug use that increases risk to the subject or to others or may affect the results, as judged by the Qualified Investigator.
• Unwillingness or inability to comply with experimental procedures and to follow INQUIS safety guidelines.
• Known intolerance, sensitivity, or allergy to any ingredients in the study test meals.
• Subject is currently participating or recently (within 30 days of screening) participated in a clinical trial involving long-term exposure (greater than 24 hours) to an investigational drug, nutritional supplement, or lifestyle modification

Sponsors & Collaborators

• INQUIS Clinical Research: lead

Study Sites (1)

INQUIS Clinical Research

Toronto, Ontario, M5C2N8, Canada

Location

MeSH Terms

Conditions

Prediabetic State; Insulin Resistance

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Hyperinsulinism

Study Officials

• Thomas Wolever, PhD, DM

  INQUIS Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Those measuring glucose and insulin
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 12, 2025
• First Posted: September 15, 2025
• Study Start: September 8, 2025
• Primary Completion: November 24, 2025
• Study Completion: December 1, 2025
• Last Updated: April 14, 2026

Record last verified: 2026-01

Locations

CA (1)